AxoGen Q2 revenue up 18.3%, beats estimates
Overview
AxoGen Q2 revenue rises 18.3% yr/yr, beating analyst expectations, per LSEG data
Adjusted EPS for Q2 beats consensus, reflecting improved operational performance
Co raises full-year revenue growth guidance to at least 17%
Outlook
AxoGen raises full-year revenue guidance to at least 17% growth
Company expects 2025 revenue of $219 mln
AxoGen anticipates gross margin of 73% to 75% for 2025
Company expects net cash flow positive for full year
Result Drivers
BROAD-BASED GROWTH - AxoGen reports double-digit revenue growth across all markets, including Extremities, Oral Maxillofacial & Head and Neck, and Breast
EXPANDED COVERAGE - Co adds 10 mln new covered lives for nerve repair solutions, increasing total coverage to over 55% among commercial payers
GROSS MARGIN IMPROVEMENT - Gross margin increased to 74.2%, reflecting improved operational efficiency
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $56.70 mln | $52.70 mln (8 Analysts) |
Q2 Adjusted EPS | Beat | $0.12 | $0.06 (6 Analysts) |
Q2 Adjusted Net Income | $5.70 mln | ||
Q2 Net Income | $600,000 | ||
Q2 Adjusted EBITDA | $9.30 mln | ||
Q2 Gross Margin | 74.2% |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for AxoGen Inc is $24.00, about 47.7% above its August 4 closing price of $12.55
The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 46 three months ago
Press Release:
